Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect? (Q44061187)

29 November 2017

Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect? (English)

1 reference

29 November 2017

0 references

1 reference

Eberhard Standl

1

1 reference

PubMed ID

25283263

29 November 2017

Michael Erbach

series ordinal

2

1 reference

PubMed ID

25283263

29 November 2017

Oliver Schnell

series ordinal

3

1 reference

29 November 2017

1 December 2014

1 reference

Current treatment options in cardiovascular medicine

29 November 2017

1 reference

29 November 2017

16

1 reference

29 November 2017

12

1 reference

29 November 2017

353

1 reference

https://scigraph.springernature.com/pub.10.1007/s11936-014-0353-y

29 November 2017

0 references

cites work

A new look at the heart in diabetes mellitus: from ailing to failing

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Neuropeptide Y Y2 receptor in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0353-Y

Heart failure and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25283263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25283263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25283263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11936-014-0353-Y

1 reference

29 November 2017

1 reference

PubMed ID

25283263